Trisodium citrate: An alternative to unfractionated heparin for hemodialysis catheter dwells

Pharmacotherapy

Volumn 30, Issue 11, 2010, Pages 1150-1158

  Pierce, Dwayne A ^a   Rocco, Michael V ^b  

^a WAKE FOREST BAPTIST HEALTH   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulants; Catheter; Citrate; Hemodialysis; Locking solution; Permacath; Permcath

Indexed keywords

CITRATE TRISODIUM; HEPARIN;

ANTICOAGULATION; ANTIMICROBIAL ACTIVITY; BACTERIAL CELL WALL; BACTERIUM CONTAMINATION; BIOFILM; BLEEDING; BLOODSTREAM INFECTION; BRAIN HEMORRHAGE; CATHETER INFECTION; CATHETER THROMBOSIS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DIGITAL PARESTHESIA; DRUG COST; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG STABILITY; DRUG STERILITY; EPISTAXIS; FACIAL PARESTHESIA; GASTROINTESTINAL HEMORRHAGE; HEART ARREST; HEMARTHROSIS; HEMODIALYSIS; HEMOPTYSIS; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; HYPOCALCEMIA; INDWELLING CATHETER; METALLIC TASTE; ORAL PARESTHESIA; PARESTHESIA; PERIORAL PARESTHESIA; PERIPHERAL PARESTHESIA; REVIEW; SHELF LIFE; SIDE EFFECT; TASTE;

ANTICOAGULANTS; CATHETERS, INDWELLING; CITRATES; COST-BENEFIT ANALYSIS; DRUG COSTS; HEPARIN; HUMANS; PRODUCT RECALLS AND WITHDRAWALS; RENAL DIALYSIS; RISK;

EID: 78149300095     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.11.1150     Document Type: Review

References (49)

1. United States Renal Data System. 2009 USRDS annual data report, section D: treatment modalities. Available from http://www.usrds.org/2009/ref/D-Ref-09. pdf. Accessed May 5, 2010.
2. National Kidney Foundation. National Kidney Foundation kidney disease outcome quality initiative. Clinical practice recommendations for guideline 7: prevention and treatment of catheter and port complications: 2006 update. Available from http://www.kidney.org/ professionals/kdoqi/pdf/12-50- 0210-JAG-DCP-Guidelines-VA-Oct06-SectionC-ofC.pdf. Accessed April 19, 2010.
3. Rayner H, Pisoni R, Gillespie B, et al. Creation, cannulation and survival of arteriovenous fistulae: data from the dialysis outcomes and practice patterns study. Kidney Int 2003;63: 323-30. (Pubitemid 35463937)
4. Butterly D, Schwab S. Catheter access for hemodialysis: an overview. Semin Dial 2001;14:411-15.
5. Ponikvar R. Hemodialysis catheters. Ther Apher Dial 2005;9:218-22.
6. Karaaslan H, Peyronnet P, Benevent D, Lagarde C, Rince M, Leroux-Robert C. Risk of heparin lock-related bleeding when using indwelling venous catheter in hemodialysis. Nephrol Dial Transplant 2001;16: 2072-4. (Pubitemid 32970572)
7. Schwab SJ, Beathard G. The hemodialysis catheter conundrum: hate living with them, but can't live without them. Kidney Int 1999;56:1-17. (Pubitemid 29300516)
8. Winnett G, Nolan J, Miller M, Ashman N. Trisodium citrate 46.7% selectively and safely reduces staphylococcal catheter-related bacteraemia Nephrol Dial Transplant 2008;23:3592-8.
9. Pepper R, Gale D, Wajed J, et al. Inadvertent postdialysis anticoagulation due to heparin line locks. Hemodial Int 2007;11:430-4. (Pubitemid 47534868)
10. Yevzlin A, Sanchez R, Hiatt J, et al. Concentrated heparin lock is associated with major bleeding complications after tunneled hemodialysis catheter placement. Semin Dial 2007;20:351-4.
11. Grudzinski L, Quinan P, Kwok S, Pierratos A. Sodium citrate 4% locking solution for central venous dialysis catheters - an effective, more cost-efficient alternative to heparin. Nephrol Dial Transplant 2007;22:471-6. (Pubitemid 46189891)
12. Rioux JP, Bortoli B, Troyanov S, Madore F. The effect of sodium citrate 4% locking solution for central venous dialysis catheter on the international normalized ratio (INR) value [letter]. Nephrol Dial Transplant 2008;23:1772-3. (Pubitemid 351767768)
13. Bayes B, Bonal J, Romero R. Sodium citrate for filling hemodialysis catheters [letter]. Nephrol Dial Transplant 1999;14:2532-3.
14. Muslimani A, Ricaurte B, Daw H. Immune heparin-induced thrombocytopenia resulting from preceding exposure to heparin catheter flushes. Am J Hematol 2007;82:652-5.
15. Dai M, Hsich A, Chao T. Catastrophic heparin-induced thrombocytopenia/ thrombosis related to the use of a Port-a- Cath in a breast cancer patient receiving chemotherapy. Support Care Cancer 2004;12:537-9.
16. Mon C, Moreno G, Ortiz M, et al. Treatment of hirudin overdosage in a dialysis patient with heparin-induced thrombocytopenia with mixed hemodialysis and hemofiltration treatment. Clin Nephrol 2006;66:302-5.
17. MacRae J, Dojcinovic I, Djurdjev O, et al. Citrate 4% versus heparin and the reduction of thrombosis study (CHARTS). Clin J Am Soc Nephrol 2008;3:369-74.
18. Lok C, Appleton D, Bhola C, Khoo B, Richardson R. Trisodium citrate 4% an alternative to heparin capping of haemodialysis catheters. Nephrol Dial Transplant 2007;22:477-83.
19. Power A, Duncan N, Singh SK, et al. Sodium citrate versus heparin catheter locks for cuffed central venous catheters: a single center randomized controlled trial. Am J Kidney Dis 2009;53:1034-41.
20. Weijmer M, van den Dorpel M, Van de Ven P, et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol 2005;16:2769-77.
21. Plamondon I, Agharazii M, Audy E, Langlois S, Desmeules S. Randomized cross-over comparison of 4% citrate and heparin for catheter lock of double-lumen hemodialysis catheters [abstract TH-FC054]. J Am Soc Nephrol 2005;16:12A.
22. Flanigan M, Pillbury L, Sadewasser G, Lim V. Regional hemodialysis anticoagulation: hypertonic tri-sodium citrate or anticoagulant citrate dextrose-A. Am J Kidney Dis 1996;27: 519-24.
23. Bagshaw SM, Laupland KB, Boiteau PJ, Godinez-Luna T. Is regional citrate superior to systemic heparin anticoagulation for continuous renal replacement therapy? A prospective observational study in an adult regional citrate care system. J Crit Care 2005;20:155-61. (Pubitemid 41219636)
24. Polaschegg HD, Sodemann K. Risks related to catheter locking solutions containing concentrated citrate [letter]. Nephrol Dial Transplant 2003;18:2688-9. (Pubitemid 37483820)
25. Payne S, Mackinnon K, Keeney M, Morrow B, Kovacs M. Effect of 3.2 vs. 3.8% sodium citrate concentration on anti-Xa levels for patients on therapeutic low molecular weight heparin. Clin Lab Haematol 2003;25:317-19.
26. Rock G, Tittley P, Fuller V. Effect of citrate anticoagulants on factor VIII levels in plasma. Transfusion 1988;28:248-52.
27. Fenwal Blood Technologies. Anticoagulant citrate products. Available from http://www.fenwalinc.com/En/Pages/Search- Results.aspx?k=citrate&s=En. Accessed January 15, 2010.
28. U.S. Food and Drug Administration. FDA issues warning on TriCitrasol, April 2000. Available from http://www.taurolock. de/uploads/downloads/deu/FDA. pdf. Accessed April 19, 2010.
29. U.S. Food and Drug Administration. FDA product approval and new drug applications. Available from http://www.fda.gov/ BiologicsBloodVaccines/ DevelopmentApprovalProcess/Biological ApprovalsbyYear/ucm179128.htm. Accessed April, 2010.
30. Raad I, Fang X, Keutgen X, Jiang Y, Sherertz R, Hachem R. The role of chelators in preventing biofilm formation and catheter-related bloodstream infections. Curr Opin Infect Dis 2008;21:385-92.
31. Shanks R, Sargent J, Martinez R, Graber M, O'Toole G. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant 2006;21:2247-55. (Pubitemid 44295052)
32. Weijmer M, Debets-Ossenkopp Y, van de Vondervoort FJ, ter Wee P. Superior antimicrobial activity of trisodium citrate over heparin for catheter locking. Nephrol Dial Transplant 2002;17:2189-95. (Pubitemid 35446677)
33. Diskin, CJ, Stokes, TJ, Dansby L, Radcliff L, Carter T. Catheter locks, heparin and biofilm: what is the risk [letter]? Nephol Dial Transplant 2008;23:2708-9.
34. Diskin CJ. Heparin, biofilm, and catheter-related sepsis [letter]. Diagn Microbiol Infect Dis 2008;61:80-1.
35. Shanks R, Donegan N, Graber M, et al. Heparin stimulates Staphylococcus aureus biofilm formation. Infect Immun 2005;73:4596-606.
36. Bosma J, Siegert C, Peerbooms P, Weijmer M. Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial. Nephrol Dial Transplant 2010;25:1213-17.
37. Yahav D, Rozen-Zvi B, Gafter-Gvili A, Leibovici L, Gafter U, Paul M. Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systemic review and meta-analysis of randomized, controlled trials. Clin Infect Dis 2008;47:83-93. (Pubitemid 351920592)
38. Moran J, Ash S, for the Clinical Practice Committee. Locking solutions for hemodialysis catheters: heparin and citrate - a position paper by ASDIN. Semin Dial 2008;21:490-2.
39. Punt CD, Boer WE. Cardiac arrest following injection of concentrated trisodium citrate [letter]. Clin Nephrol 2008;69: 317-18.
40. Charney DI, Salmond R. Cardiac arrest after hypertonic citrate anticoagulation for chronic hemodialysis. ASAIO Trans 1990;36:M217-19.
41. Uhl L, Maillet S, King S, Kruskall MS. Unexpected citrate toxicity and severe hypocalcemia during apheresis. Transfusion 1997;37:1063-5.
42. Sungur M, Eryuksel E, Yavas S, Bihorac A, Layon AJ, Caruso L. Exit of catheter lock solutions from double lumen acute hemodialysis catheters - an in vitro study. Nephrol Dial Transplant 2007;22:3533-7.
43. Doorenbos C, Van den Elsen-Hutten M, Heuven M, Hessels J. Estimation of trisodium citrate (Citra-Lock™) remaining in central venous catheters after the interdialytic interval. Nephrol Dial Transplant 2006;21:543-5. (Pubitemid 43160019)
44. Agharazii M, Plamondon I, Lebel M, Douville P, Desmeules S. Estimation of heparin leak into the systemic circulation after central venous catheter heparin lock. Nephrol Dial Transplant 2005;20:1238-40. (Pubitemid 40862117)
45. Willicombe M, Vernon K, Davenport A. Embolic complications from central venous hemodialysis catheters used with hypertonic citrate locking solution. Am J Kidney Dis 2010;55: 348-51.
46. Stranz M, Hadaway L. Risk of bacterial contamination from citrate catheter locks [letter]. Semin Dial 2009;22:704.
47. American Society of Health-System Pharmacists and Baxter Healthcare Corporation. The ASHP discussion guide on USP chapter 〈797〉 for compounding sterile preparations: summary of revisions to USP chapter 〈797〉. Available from http://www.ashp.org/s-ashp/docs/files/ discguide797-2008.pdf. Accessed April 19, 2010.
48. Levesque N, Girard L, Leger J, Dorval M. Stability of trisodium citrate 4.0% and 46.7% in polyvinyl chloride syringes. Can J Hosp Pharm 2001;54:264-8.
49. Wazny L, Walker S, Moist L. Visual compatibility of gentamicin sulfate and 4% sodium citrate solutions [letter]. Am J Health-Syst Pharm 2005;62:1548-9.